Penn Medicine Abramson Cancer Center


 

Penn Medicine Updates in Oncology 2023: Study EV-103 Dose Escalation/Cohort A - Long-Term Outcome of Enfortumab Vedotin + Pembro in 1L Cis-Ineligible Stage 3/4 UC With Nearly 4 Years of Follow-Up

0 views
July 12, 2023
Comments 0
Login to view comments. Click here to Login